In this study, for more efficient targeting of METTL3 in AML, we developed and evaluated a Von Hippel-Lindau (VHL)-recruiting METTL3 PROTAC, ZW27941, that effectively degrades METTL3, thus temporarily eliminating all functions of the protein and demonstrating enhanced anti-leukemic activity. This evidence concerns the gene VHL and acute myeloid leukemia.